
Research commissioned by Innovate UK and the British In Vitro Diagnostics Association (BIVDA) has revealed that the NHS could save …

This week, shares in Sarepta Therapeutics rocketed by 80% after the company released preliminary data from a Phase 1/2a trial …

Kallyope and Novo Nordisk have entered into a research collaboration and option agreement to discover novel peptide therapeutics for the …

A blood test designed to support the clinical determination of whether a child is on the autistic spectrum has been …

Despite its highly-publicised transgressions recently, tech giant Facebook is looking to do the right thing by wading into the ongoing …

CAR-T is emerging as one of the most potentially exciting therapies in the industry, particularly as a beacon for the …

Biogen currently has the only product on the market approved to treat spinal muscular atrophy (SMA), in Spinraza, and that …

Beleaguered pharma firm Valeant has come up against another bump in the road as its plaque psoriasis lotion Duobrii (halobetasol …

Roche has clearly seen significant potential in Foundation Medicine’s work in genomics to pay $2.4 billion to take complete ownership …

Going from the youngest female self-made billionaire in the world to being charged with engaging in schemes to defraud investors …

Dr Reddy’s Laboratories has taken two steps forward an one step back after its generic version of Suboxone Film (buprenorphine/naloxone) …

From breach scandals to GDPR, data is becoming a more prominent part of our everyday lives. This holds great potential …

Since the introduction of the vaccination against the Human Papilloma Virus in 2008, there has been an 86% drop in …

With the advent of another week, there’s another trial discontinuation in the industry as Teva announces its decision to terminate …

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

Theresa May finally attempted to tackle the elephant in the room for the UK government, well, the one other than …

Another busy in week in pharma has seen a number of companies release promising data on their drugs, Roche’s study …

Allergan has announced another move in its “refreshment” of its executive Board of Directors with the appointment of Thomas C …

Teva has been doing some major global restructuring since Kare Schultz came to the helm of the embattled, Israeli drugmaker. …

Roche’s ongoing dispute with UK health service watchdog NICE over the availability of its monoclonal antibody Perjeta (pertuzumab) on the …